Trial finds experimental chikungunya vaccine CHIKV VLP is safe

Trial finds experimental chikungunya vaccine CHIKV VLP is safe

A Phase 2 trial by the National Institute of Allergy and Infectious Diseases (NIAID) of an experimental chikungunya vaccine has been found to be safe and well-tolerated, producing durable immune responses in healthy volunteers. Detailed in a paper published in The Journal of the American Medical Association (JAMA) in May, the NIAID trial comprised 400 […]

NIAID Study Finds Current Cambodia Malaria Treatment Fails

NIAID Study Finds Current Cambodia Malaria Treatment Fails

New findings from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), confirm dihydroartemisinin-piperaquine, the first-line treatment for Plasmodium falciparum malaria infection in Cambodia, has failed in certain provinces due to parasite resistance to artemisinin and piperaquine. Dihydroartemisinin-piperaquine is an artemisinin combination therapy (ACT) for malaria that […]